Changfeng Pharmaceuticals (02652.HK): Clinical trial application for Allopatadine Mometasone nasal spray accepted by NMPA.

Zhiclass Financial APP News, Changfeng Pharmaceutical (02652.HK) announced that the clinical trial application for the fixed compound formulation of olodaterol mometasone nasal spray (product) independently developed by the company has received a notice of acceptance from the National Medical Products Administration (NMPA) of China.